Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

1.530 UNCHANGED
Streaming Delayed Price Updated: 12:08 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 196,566
Open 1.550
Bid (Size) 1.520 (74)
Ask (Size) 1.530 (8)
Prev. Close 1.530
Today's Range 1.510 - 1.569
52wk Range 1.140 - 5.960
Shares Outstanding 417,247,333
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks are moving in today's session
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
 
Via Benzinga

Performance

YTD
-46.3%
-46.3%
1 Month
-62.4%
-62.4%
3 Month
-58.5%
-58.5%
6 Month
-3.2%
-3.2%
1 Year
-63.6%
-63.6%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Earnings Scheduled For August 7, 2025
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
US Stocks Mixed; Dow Falls 100 Points
Via Benzinga
Topics Stocks
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss
Via Benzinga
Monday's session: gap up and gap down stocks
Via Chartmill
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wondering what's happening in today's pre-market session?
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Could This New Drug Be The Safer Way To Fight Obesity?
Via Benzinga
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data
Via Benzinga
Skye (SKYE) Q2 R&D Soars 249% No Revenue
Via The Motley Fool
Topics Intellectual Property
In today's session, these stocks are experiencing unusual volume.
Via Chartmill
What's going on in today's session
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Via Chartmill
These stocks are moving in today's pre-market session
Via Chartmill
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Top stock movements in today's session.
Via Chartmill
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Via Benzinga
Tuesday's session: top gainers and losers
Via Chartmill

Frequently Asked Questions

Is Skye Bioscience, Inc. - Common Stock publicly traded?
Yes, Skye Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Skye Bioscience, Inc. - Common Stock trade on?
Skye Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Skye Bioscience, Inc. - Common Stock?
The ticker symbol for Skye Bioscience, Inc. - Common Stock is SKYE on the Nasdaq Stock Market
What is the current price of Skye Bioscience, Inc. - Common Stock?
The current price of Skye Bioscience, Inc. - Common Stock is 1.530
When was Skye Bioscience, Inc. - Common Stock last traded?
The last trade of Skye Bioscience, Inc. - Common Stock was at 10/16/25 12:08 PM ET
What is the market capitalization of Skye Bioscience, Inc. - Common Stock?
The market capitalization of Skye Bioscience, Inc. - Common Stock is 638.39M
How many shares of Skye Bioscience, Inc. - Common Stock are outstanding?
Skye Bioscience, Inc. - Common Stock has 638M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.